CAGRI-PH2-DOSEFIND — design and population

§2Design and population

§2.1Design and allocation

Design class

Randomised, double-blind, placebo-controlled dose-finding study

Masking

Double-blind

Arms

5

Allocation

Randomised across dose arms and a common comparator

Endpoint adjudication

Not applicable to the primary endpoint of this design

Data monitoring

As specified in the protocol

§2.2Arms

Table 2. Randomised arms. Illustrative: arm-level allocations are reconstructed by the Institute from the design class and the randomised total where the published report does not state them.

§2.3Population

Indication. Obesity and overweight in adults

Excess adiposity sufficient to impair health, operationalised in the pivotal incretin programmes as a body-mass index of 30 kg/m² or above, or 27 kg/m² or above with at least one weight-related comorbidity.

Geographic footprint. Canada · Norway · Spain · Israel · Republic of Korea · Brazil · Argentina · India.

§2.4Eligibility as the Institute reads it

• Included. Excess adiposity sufficient to impair health, operationalised in the pivotal incretin programmes as a body-mass index of 30 kg/m² or above, or 27 kg/m² or above with at least one weight-related comorbidity.
• Excluded. Participants for whom the intervention is contraindicated, including not established — investigational compound. Exclusion criteria narrow the population to which the estimate applies and are the principal source of indirectness where a trial estimate is applied to ordinary practice.